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To the Editor: Therapies target-
ing tumor angiogenesis are cur-
rently one of the major approaches
in our treatment armamentarium.
Despite being well tolerated even
in the context of long term mainte-
nance, a variety of different side
effects could arise. Herein, we pres-
ent a rare case of dysphonia occur-
ring after bevacizumab
administration in an ovarian cancer
patient. While not a life-threaten-
ing event, dysphonia could consid-
erably affect quality of life. Further
studies to elucidate the exact patho-
physiology are warranted.
Angiogenesis is an identiﬁed
fundamental hallmark in carcino-
genesis and one of the benchmarks
in the modern era of cancer thera-
peutics. Different strategies have
been developed with the introduc-
tion of either monoclonal antibod-
ies, such as bevacizumab (bev) or
small molecule tyrosine kinase
inhibitors that target one or more
of the VEGFRs.
Bevacizumab is the ﬁrst VEGF
inhibitor approved by the FDA
for systemic use in cancer and con-
sists of a humanised, function-
blocking monoclonal antibody that
selectively binds to theVEGF.1 Cli-
nicians need to be aware of a variety
of different side effects such as
hypertension, proteinuria, bleed-
ing, upper respiratory infection,
thromboembolic events, diarrhoea,
gastrointestinal perforation, wound
healing complications, ﬁstulae,
reversible posterior leukoencepha-
lopathy syndrome, and congestive
heart failure. Dysphonia is certainly
a well documented, adverse eventHematol Oncol Stem Cell Ther 7(3) Third Quarter 201with platinum or vinca derivatives,
and anti-VEGF TKIs.
Herein, we present the case of a
48-year-old woman diagnosed with
a stage IV high grade serous ovarian
carcinoma in May 2012. An
extended total abdominal hysterec-
tomy, bilateral salpingo-oophorec-
tomy, omentectomy and
appendicectomy were performed
on 23/5/2012. A month later, she
was started on a Carboplatin–Pac-
litaxel three weekly combination
regimen. Due to funding issues in
Cyprus, bev was started with the
commencement of the fourth cycle
of chemotherapy instead of the sec-
ond one, for a total of 17 adminis-
trations (7.5 mg/kgr, q3w). After
the second administration of bev,
hoarseness was noted. Due to con-
tinuous deterioration of symptoms
after four injections, further investi-
gations were carried out. Examina-
tion by endoscopic laryngoscopy
revealed normal mobility, but a
mild redness of the cords and a
white plaque that covered half of
the left cord. No inﬂammation or
other signs of extra-esophageal
reﬂux disease were identiﬁed. The
patient did not mention reﬂux
related symptoms. In addition,
investigation by computed tomog-
raphy of the neck did not show
any suspicious ﬁndings. During a
two-month temporary interruption
of maintenance therapy, the voice
disorder completely resolved. After
a long discussion with the patient
due to the potential beneﬁts, the
decision to restart therapy was
made. With the ﬁrst re-administra-
tion, mild dysphonia recurred and
persisted with the subsequent
cycles, but did not worsen. She
completed her maintenance treat-
ment on November 2013. Almost
two months after the last cycle,
the voice disorder completely
resolved.4 hemoncstem.edmgr.comDysphonia has been more
prominent as an adverse event
with agents such as axitinib, aﬂib-
ercept, or regorafenib, and may
be observed in up to 77% of
patients in phase I studies. The
pathophysiological mechanism still
remains to be elucidated and sev-
eral theories have been proposed.
The hypothesis of particular
susceptibility to the vocal box cap-
illaries is supported by experi-
ments that show tracheal
epithelium in regression following
VEGF inhibition causing endothe-
lial apoptosis and a migratory
stream of pericytes to surviving
vessels.2 These particularly sensi-
tive fenestrated capillaries show a
reversible regression with VEGF
inhibition, and regenerate their
capacity within a few weeks after
cessation of the causative factor.
This could well be the case in
our patient. It becomes clear, how-
ever, that chronic inhibition could
lead to microvascular rarefaction
and more permanent damage,3
and that a neurotoxic effect of
the treatment cannot be excluded.4
Furthermore, maculae ﬂavae
located at the anterior and poster-
ior ends of the membranous parts
of the vocal cords could be a target
for further investigation.
There is no doubt that hoarse-
ness and general voice disorders
are not life-threatening side effects
but they could considerably affect
quality of life. Clinicians should
be alerted to not underestimate
this type of toxicity. Discontinua-
tion of therapy may be a reason-
able option due to a possible
permanent malfunctioning. To
our knowledge, only rare cases
are reported in the literature in
relation to bev administration,
and further studies to elucidate
the exact pathophysiology are
warranted.123
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